ข้ามไปยังเนื้อหาหลัก
QuantanSite

NVRA

NASDAQ

Novara Biotech

Healthcare · Biotechnology

Updated UTC

US$410.77

+5.46+1.35%

After hoursUS$412.82+0.50%

350.00400.0005/2106/2608/0309/0710/1311/18410.77

130 candlesRange +20.09%

Key statistics

Open
US$405.06
High
US$411.55
Low
US$402.66
Previous close
US$405.31
ปริมาณซื้อขาย
3.81M
Average volume
3.14M
มูลค่าตลาด
393.65B
P/E ratio
37.55
EPS
US$10.94
Dividend yield
—
52-week high
US$412.94
52-week low
US$295.67

Financial statements

Units: USD · Annual
ItemFY2022FY2023FY2024FY2025FY2026
Revenue31.67B37.26B41.96B48.31B53.67B
Gross profit18.76B21.53B23.9B26.46B32.34B
Operating income6.26B7.62B7.85B9.58B11.72B
Net income4.88B5.63B6.17B5.78B7.65B

About the company

Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.

Related news

Demo
  • Novara Biotech reports quarterly revenue above the internal plan

    Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.

    Sector Desk

  • Novara Biotech expands manufacturing capacity in Cambridge

    The company approved a multi-year capital program intended to shorten lead times for its largest customers.

    Sector Desk

  • Analyst note trims Novara Biotech price target on valuation

    A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.

    Sector Desk

  • Novara Biotech appoints new chief financial officer

    The board named an internal candidate with prior treasury and investor-relations experience to the role.

    Sector Desk

  • Novara Biotech announces share repurchase authorization

    The authorization covers a modest slice of the float and will be funded from operating cash flow.

    Terminal Brief